◎ Sugi Atlas

Atlas / Disease / Digestive system neuroendocrine tumor, grade 1/2

Digestive system neuroendocrine tumor, grade 1/2

disease
On this page

Also known as alimentary part of gastrointestinal system neuroendocrine tumoralimentary part of gastrointestinal system neuroendocrine tumourdigestive system NETdigestive system neuroendocrine tumordigestive system neuroendocrine tumourdigestive system well differentiated neuroendocrine tumordigestive system well differentiated neuroendocrine tumourgastroenteropancreatic NETgastroenteropancreatic neuroendocrine tumorgastroenteropancreatic neuroendocrine tumourgastrointestinal NETgastrointestinal neuroendocrine tumorgastrointestinal neuroendocrine tumorsgastrointestinal neuroendocrine tumourgastrointestinal neuroendocrine tumoursgastrointestinal system neuroendocrine tumorgastrointestinal system neuroendocrine tumourGINETmalignant gastrointestinal neuroendocrine tumormalignant gastrointestinal neuroendocrine tumour

Summary

Digestive system neuroendocrine tumor, grade 1/2 (MONDO:0000386) is a cancer (an umbrella term covering 10 Mondo subtypes) with 1 cohort gene (1 CIViC-evidence somatic driver) and 52 clinical trials. Molecularly, BRAF V600E confers sensitivity to Vemurafenib + Trametinib + Dabrafenib in Gastrointestinal Neuroendocrine Tumor (CIViC Level C). Top therapeutic interventions include edotreotide gallium ga-68, lanreotide, and lutetium oxodotreotide lu-177.

At a glance

  • Classification: Cancer
  • Umbrella term: 10 Mondo subtypes
  • Cohort genes: 1
  • Clinical trials: 52
  • Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namedigestive system neuroendocrine tumor, grade 1/2
Mondo IDMONDO:0000386
DOIDDOID:0050626
NCITC95404
UMLSC2930967
MedGen443945
GARD0022761
Anatomy (UBERON)UBERON:0005409
Is cancer (heuristic)yes

Also known as: alimentary part of gastrointestinal system neuroendocrine tumor · alimentary part of gastrointestinal system neuroendocrine tumour · digestive system NET · digestive system neuroendocrine tumor · digestive system neuroendocrine tumour · digestive system well differentiated neuroendocrine tumor · digestive system well differentiated neuroendocrine tumour · gastroenteropancreatic NET · gastroenteropancreatic neuroendocrine tumor · gastroenteropancreatic neuroendocrine tumour · gastrointestinal NET · gastrointestinal neuroendocrine tumor · gastrointestinal neuroendocrine tumors · gastrointestinal neuroendocrine tumour · gastrointestinal neuroendocrine tumours · gastrointestinal system neuroendocrine tumor · gastrointestinal system neuroendocrine tumour · GINET · malignant gastrointestinal neuroendocrine tumor · malignant gastrointestinal neuroendocrine tumour

Disease family

An umbrella term covering 10 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2

Related subtypes (6): intestinal neuroendocrine neoplasm, gastric neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm, salivary gland small cell carcinoma, liver neuroendocrine carcinoma, gallbladder neuroendocrine neoplasm

Subtypes (10): small intestine neuroendocrine tumor, well differentiated, low or intermediate grade, gastrin-producing neuroendocrine tumor, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, gastric neuroendocrine tumor, well differentiated, low or intermediate grade, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, rectal neuroendocrine tumor, gallbladder neuroendocrine tumor, grade 1/2, pancreatic neuroendocrine tumor, intestinal neuroendocrine tumor G1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 11 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

GeneintOGen roleCancer typesCIViC
BRAFActBLCA,BRCA,CHOL,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,GBM,GIST,HGGNOS,LGGNOS,LUAD,MEL,MLYM,NSCLC,OVT,PAST,PCM,PRAD,PRCC,PROSTATE,READ,SACA,SKCM,STAD,UCEC,WDTCCIViC #5

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
BRAFOrphanet:1340Cardiofaciocutaneous syndrome
BRAFOrphanet:146Differentiated thyroid carcinoma
BRAFOrphanet:251615Pilomyxoid astrocytoma
BRAFOrphanet:389Langerhans cell histiocytosis
BRAFOrphanet:500Noonan syndrome with multiple lentigines
BRAFOrphanet:54595Craniopharyngioma
BRAFOrphanet:58017Classic hairy cell leukemia
BRAFOrphanet:626Large/giant congenital melanocytic nevus
BRAFOrphanet:648Noonan syndrome
BRAFOrphanet:840Syringocystadenoma papilliferum
BRAFOrphanet:96253Cushing disease

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
civic_only1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
BRAFHGNC:1097ENSG00000157764P15056Serine/threonine-protein kinase B-rafcivic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
BRAFSerine/threonine-protein kinase B-rafProtein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Kinase127.7×0.036

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
BRAFKinaseyes2.7.10.2Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, PKC_DAG/PE

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
buccal mucosa cell1
calcaneal tendon1
colonic epithelium1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
BRAF265ubiquitousmarkerbuccal mucosa cell, colonic epithelium, calcaneal tendon

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
BRAF7,394

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
BRAFP15056131

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 39. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Signaling by MRAS-complex mutants12855.0×0.004BRAF
Signalling to p38 via RIT and RIN12284.0×0.004BRAF
Negative feedback regulation of MAPK pathway11903.3×0.004BRAF
ARMS-mediated activation11631.4×0.004BRAF
Prolonged ERK activation events11427.5×0.004BRAF
SHOC2 M1731 mutant abolishes MRAS complex function11427.5×0.004BRAF
Gain-of-function MRAS complexes activate RAF signaling11427.5×0.004BRAF
Signaling by FGFR311142.0×0.004BRAF
Signaling by FGFR411038.2×0.004BRAF
Frs2-mediated activation1951.7×0.004BRAF
Signaling by FGFR11815.7×0.004BRAF
Spry regulation of FGF signaling1713.8×0.005BRAF
Signalling to ERKs1601.0×0.005BRAF
Negative regulation of FGFR3 signaling1439.2×0.005BRAF
Signaling by RAS mutants1423.0×0.005BRAF
Negative regulation of FGFR4 signaling1407.9×0.005BRAF
Signaling by FGFR21407.9×0.005BRAF
Negative regulation of FGFR1 signaling1368.4×0.005BRAF
Negative regulation of FGFR2 signaling1368.4×0.005BRAF
Signaling by FGFR1346.1×0.005BRAF
RAF activation1335.9×0.005BRAF
Signaling by high-kinase activity BRAF mutants1317.2×0.005BRAF
MAP2K and MAPK activation1285.5×0.005BRAF
Signaling by RAF1 mutants1278.5×0.005BRAF
Negative regulation of MAPK pathway1265.6×0.005BRAF
Signaling by moderate kinase activity BRAF mutants1253.8×0.005BRAF
Paradoxical activation of RAF signaling by kinase inactive BRAF1253.8×0.005BRAF
Signaling downstream of RAS mutants1253.8×0.005BRAF
Oncogenic MAPK signaling1248.3×0.005BRAF
Signaling by NTRK1 (TRKA)1196.9×0.007BRAF

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
CD4-positive or CD8-positive, alpha-beta T cell lineage commitment15617.3×0.003BRAF
positive regulation of axon regeneration13370.4×0.003BRAF
negative regulation of synaptic vesicle exocytosis13370.4×0.003BRAF
CD4-positive, alpha-beta T cell differentiation12808.7×0.003BRAF
myeloid progenitor cell differentiation12407.4×0.003BRAF
positive regulation of D-glucose transmembrane transport12106.5×0.003BRAF
head morphogenesis12106.5×0.003BRAF
establishment of protein localization to membrane11872.4×0.003BRAF
negative regulation of fibroblast migration11532.0×0.003BRAF
endothelial cell apoptotic process11296.3×0.003BRAF
regulation of T cell differentiation11203.7×0.003BRAF
face development1802.5×0.003BRAF
synaptic vesicle exocytosis1766.0×0.003BRAF
positive regulation of peptidyl-serine phosphorylation1766.0×0.003BRAF
stress fiber assembly1766.0×0.003BRAF
postsynaptic modulation of chemical synaptic transmission1674.1×0.004BRAF
positive regulation of axonogenesis1581.1×0.004BRAF
thyroid gland development1543.6×0.004BRAF
negative regulation of endothelial cell apoptotic process1495.6×0.004BRAF
T cell differentiation in thymus1411.0×0.005BRAF
positive regulation of substrate adhesion-dependent cell spreading1374.5×0.005BRAF
substrate adhesion-dependent cell spreading1343.9×0.005BRAF
thymus development1337.0×0.005BRAF
ERK1 and ERK2 cascade1318.0×0.005BRAF
positive regulation of stress fiber assembly1312.1×0.005BRAF
visual learning1306.4×0.005BRAF
long-term synaptic potentiation1280.9×0.005BRAF
epidermal growth factor receptor signaling pathway1247.8×0.006BRAF
somatic stem cell population maintenance1247.8×0.006BRAF
cellular response to xenobiotic stimulus1240.7×0.006BRAF

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
BRAFVEMURAFENIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
BRAF484

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
VEMURAFENIB4BRAF
PONATINIB4BRAF
FEDRATINIB4BRAF
SORAFENIB4BRAF
DASATINIB ANHYDROUS4BRAF
RUXOLITINIB4BRAF
INFIGRATINIB PHOSPHATE4BRAF
INFIGRATINIB4BRAF
REGORAFENIB4BRAF
DABRAFENIB4BRAF
COBIMETINIB4BRAF
NILOTINIB4BRAF
ABEMACICLIB4BRAF
ENCORAFENIB4BRAF
TOVORAFENIB4BRAF
PAZOPANIB4BRAF
DASATINIB4BRAF
ERLOTINIB4BRAF
GEFITINIB4BRAF
IMATINIB4BRAF
MASITINIB3BRAF
AVUTOMETINIB3BRAF
NAPORAFENIB3BRAF
QUERCETIN3BRAF
MOTESANIB3BRAF
DORAMAPIMOD2BRAF
FORETINIB2BRAF
REBASTINIB2BRAF
CEP-324962BRAF
BAFETINIB2BRAF

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
BRAF1,442Binding:1400, Functional:37, ADMET:5

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
BRAF2.7.10.2, 2.7.11.1non-specific protein-tyrosine kinase, non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
BRAF1,442

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

CompoundMax phaseCohort target (bioactivity)
VEMURAFENIB4BRAF
PONATINIB4BRAF
FEDRATINIB4BRAF
SORAFENIB4BRAF
DASATINIB ANHYDROUS4BRAF
RUXOLITINIB4BRAF
INFIGRATINIB PHOSPHATE4BRAF
INFIGRATINIB4BRAF
REGORAFENIB4BRAF
DABRAFENIB4BRAF
COBIMETINIB4BRAF
NILOTINIB4BRAF
ENCORAFENIB4BRAF
TOVORAFENIB4BRAF
PAZOPANIB4BRAF
DASATINIB4BRAF
ERLOTINIB4BRAF
GEFITINIB4BRAF
IMATINIB4BRAF
MASITINIB3BRAF
AVUTOMETINIB3BRAF
NAPORAFENIB3BRAF
QUERCETIN3BRAF
MOTESANIB3BRAF
DORAMAPIMOD2BRAF
FORETINIB2BRAF
REBASTINIB2BRAF
CEP-324962BRAF
BAFETINIB2BRAF

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1BRAF
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 52.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified15
PHASE214
PHASE36
PHASE1/PHASE26
PHASE16
PHASE42
PHASE2/PHASE32
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05701241PHASE4RECRUITINGContinuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
NCT04524442PHASE4COMPLETEDPost-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
NCT05477576PHASE3RECRUITINGStudy of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT05884255PHASE3RECRUITINGAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT06091748PHASE3RECRUITINGGallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
NCT06784752PHASE3RECRUITINGStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT07165886PHASE2/PHASE3RECRUITINGSirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
NCT01842165PHASE3COMPLETED177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
NCT02608203PHASE2/PHASE3COMPLETED[68 Ga]-DOTANOC PET/CT in GEP-NETs
NCT04852679PHASE3COMPLETEDStudy to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
NCT02185443PHASE2RECRUITINGStereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
NCT03891784PHASE2ACTIVE_NOT_RECRUITINGAbemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
NCT04711135PHASE2ACTIVE_NOT_RECRUITINGStudy to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT05636618PHASE1/PHASE2RECRUITINGTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT05988918PHASE2ACTIVE_NOT_RECRUITINGMulticenter Trial of ESK981 in Patients With Select Solid Tumors
NCT05997056PHASE2RECRUITINGTrial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
NCT06427798PHASE1/PHASE2RECRUITINGSomatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
NCT06790706PHASE2RECRUITINGIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
NCT01648465PHASE2TERMINATEDStudy of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
NCT01994213PHASE2TERMINATEDA Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
NCT02078843PHASE1/PHASE2TERMINATEDDiagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
NCT02162446PHASE1/PHASE2COMPLETED68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
NCT02231762PHASE2COMPLETEDCombination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
NCT02611024PHASE1/PHASE2COMPLETEDPharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT03043664PHASE1/PHASE2COMPLETEDStudy of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
NCT03963193PHASE2UNKNOWNEtoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
NCT03980925PHASE2COMPLETEDPlatinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
NCT04505553PHASE2COMPLETEDOral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
NCT04915144PHASE2WITHDRAWN177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
NCT05987176PHASE2TERMINATEDComparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
NCT04609592PHASE1RECRUITINGStudy of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
NCT05262556PHASE1ACTIVE_NOT_RECRUITINGNP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
NCT06479811PHASE1RECRUITING[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
NCT07150546PHASE1RECRUITINGCombination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
NCT07165132PHASE1RECRUITINGStudy of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT05411133PHASE1COMPLETEDTreatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
NCT05359146EARLY_PHASE1UNKNOWNCombined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
NCT04090034Not specifiedRECRUITINGPeptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
NCT05064150Not specifiedACTIVE_NOT_RECRUITINGNeuroendocrine Tumors - Patient Reported Outcomes
NCT05196087Not specifiedRECRUITINGNon-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
EDOTREOTIDE GALLIUM GA-6844
LANREOTIDE43
LUTETIUM OXODOTREOTIDE LU-17743
OCTREOTIDE42
ABEMACICLIB41
LURBINECTEDIN41
SUNITINIB41
ACTINIUM AC 225 DOTATATE31
ARGININE31
DOMVANALIMAB31
FAMITINIB31
SOMATOSTATIN31
ZIMBERELIMAB31
LUTETIUM LU177 EDOTREOTIDE22
CABOTAMIG21
LYSINE21
SATOREOTIDE TRIZOXETAN21
CHEMBL335003702
CHEMBL27511701
CHEMBL451771401
CHEMBL540543601
CHEMBL539702801
CHEMBL519022501
SCEPTRIN01

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtypeTherapyEffectLevelCIViC
BRAF V600EVemurafenib + Trametinib + DabrafenibSensitivity/ResponseCIViC CEID1430

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 73

This page pulls from 73 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergardgenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterprointogenmedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptuberonufeatureumlsuniprot